human brn2 sirna (Santa Cruz Biotechnology)
Structured Review

Human Brn2 Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/array+scan+vti+software/Brn-2+siRNA/pmc11822115-82-0-4
Average 93 stars, based on 1 article reviews
Images
1) Product Images from "PlexinD1 is a driver and a therapeutic target in advanced prostate cancer"
Article Title: PlexinD1 is a driver and a therapeutic target in advanced prostate cancer
Journal: EMBO Molecular Medicine
doi: 10.1038/s44321-024-00186-z
Figure Legend Snippet: ( A ) GSEA plots of transmembrane RTK-related gene sets enriched in PlexinD1-knockdown vs. control 22Rv1 cells, and PLXND1 -high vs. -low PCa patient samples in TCGA cohort. ( B ) Representative images of a RTK phosphorylation antibody array and quantification of p-ErbB3 levels in control and PlexinD1-knockdown C4-2B ENZR cells ( n = 2 technical replicates). The raw values from measurement of p-ErbB3 spot intensity after background subtraction are presented. ( C ) Western blot of p-ErbB3, p-ErbB2, p-cMet, p-ERK, p-AKT, and their total protein forms in control and PlexinD1-knockdown C4-2B ENZR and 22Rv1 cells. ( D ) qPCR of ErbB3 ( NRG1 and NRG2 ) and cMet ( HGF ) ligand mRNA levels in control and PlexinD1-knockdown C4-2B ENZR and 22Rv1 cells ( n = 3 biological replicates). ( E ) Representative PLA images and quantification of PlexinD1-ErbB3/cMet interaction by per-cell cytoplasmic fluorescence intensity in C4-2B ENZR cells treated with recombinant Sema3E/Sema3C proteins (200–500 ng/ml, 4 h) or SEMA3E / SEMA3C siRNA (10 μM, 48 h). PlexinD1 antibody incubation alone served as negative controls. The n of each group indicates the number of cells examined for quantification. Scale bars: 5 μm. ( F ) Co-IP assays of PlexinD1-ErbB3/cMet interaction in 22Rv1 cells. IgG was used in the IP step as negative control. Five percent of input was blotted as positive control. ( G ) Cell proliferation assays of 22Rv1 cells pre-treated with an ErbB3 neutralizing antibody (100 ng/ml, 24 h) or SGX-523 (5 µM, 24 h) and then subjected to PLXND1 siRNA addition followed by a 5-day observation period, and control and PlexinD1-overexpressing LNCaP cells upon treatment with an ErbB3 neutralizing antibody or SGX-523 during a 5-day observation period. Data represent the fold changes of cell proliferation on day 5 relative to siRNA treatment day (day 1) for 22Rv1 cells or treatment day (day 1) for LNCaP cells ( n = 3 biological replicates), with fold changes in non-treated groups of control cells set as 1 for normalization of other groups. ( H ) qPCR of stemness, basal, and NE markers as indicated in 22Rv1 cells receiving an ErbB3 neutralizing antibody (100 ng/ml, 24 h), SGX-523 (5 µM, 24 h), or transient transfection of ErbB3/cMet expression plasmids followed by PLXND1 siRNA treatment for another 48 h ( n = 3 biological replicates). ( I ) qPCR of stemness, basal, NE, and EMT markers as indicated in control and PlexinD1-overexpressing LNCaP cells upon treatment with 100 ng/ml ErbB3 neutralizing antibody or 5 µM SGX-523 for 24 h ( n = 3 biological replicates). Data information: In ( B , D , E , G , H , I ), data are presented as mean ± SEM. In ( A ), P values were determined by permutation test. In ( B , D ), P values were determined by unpaired two-tailed Student’s t -test. In ( E ), P values were determined by one-way ANOVA with Dunnett’s multiple comparisons test. In ( G , H , I ), P values were determined by two-way ANOVA with Tukey’s multiple comparisons test. * P < 0.05, ** P < 0.01; ns, not significant. Exact P values are listed in Appendix Table . .
Techniques Used: Knockdown, Control, Phospho-proteomics, Ab Array, Western Blot, Fluorescence, Recombinant, Incubation, Co-Immunoprecipitation Assay, Negative Control, Positive Control, Transfection, Expressing, Two Tailed Test
Figure Legend Snippet: ( A ) IPA upstream regulator analysis of RNA-seq data from PlexinD1-knockdown vs. control C4-2B ENZR cells, with significantly downregulated hits shown (absolute value of z-score of ≥2, p < 0.05). ( B ) STRING analysis of Gli1 linked to multiple stemness, NE, and EMT marker and/or driver genes. ( C ) Western blot of Gli1 in control and PlexinD1-manipulated PCa cells. ( D ) Determination of Gli-Luc reporter activity in control and PlexinD1-manipulated PCa cells ( n = 3 biological replicates). ( E ) qPCR of Gli1 target genes in control and PlexinD1-knockdown C4-2B ENZR cells ( n = 3 biologial replicates). ( F ) qPCR of Hh ligands in control and PlexinD1-knockdown C4-2B ENZR and 22Rv1 cells ( n = 3 biological replicates). ( G ) Determination of Gli-Luc reporter activity in 22Rv1 cells receiving an ErbB3 neutralizing antibody (100 ng/ml, 24 h), SGX-523 (5 µM, 24 h), or transient transfection of ErbB3/cMet expression plasmids followed by PLXND1 siRNA treatment for another 48 h ( n = 3 biological replicates), and in control and PlexinD1-overexpressing LNCaP cells upon treatment with 100 ng/ml ErbB3 neutralizing antibody or 5 µM SGX-523 for 24 h ( n = 3 biological replicates). ( H ) Representative images of Gli1 (red color) and α-tublin (a cytoplasm marker, green color) co-IF images and quantification of Gli1+ cells in the nuclei of control and PlexinD1-manipulated 22Rv1 and LNCaP cells under the conditions as in ( G ) ( n = 3 biological replicates). Scale bars: 10 µm. ( I ) Western blot of Gli1 in nuclear and cytoplasmic fractions of control and PlexinD1-manipulated 22Rv1 and LNCaP cells under the conditions as in ( G ). ( J ) Cell proliferation assays of control and PlexinD1-overexpressing LNCaP cells upon treatment with 10 µM cyclopamine or 5 µM GANT61 for 5 days ( n = 3 biological replicates). ( K ) Cell proliferation assays of C4-2B ENZR and 22Rv1 cells upon treatment with 10 µM cyclopamine or 5 µM GANT61 for 5 days ( n = 3 biological replicates). ( L ) qPCR of stemness, NE and EMT markers in control and PlexinD1-overexpressing LNCaP cells under treatment with GANT61 (5 µM, 24 h) ( n = 3 biological replicates). ( M ) GSEA plots of two Hh signaling-related gene sets enriched in PLXND1 -high vs. -low PCa patient samples from TCGA cohort. ( N ) Chi-square analysis of distribution of select Gli1 target gene mRNA expression (L, low; H, high) in PLXND1 -low and -high PCa patient samples from TCGA cohort. Data information: In ( D – H , J – L ), data are presented as mean ± SEM. In ( A ), P values were determined by Fisher’s exact test. In ( D – F , K ), P values were determined by one-way ANOVA with Dunnett’s multiple comparisons test [for C4-2B ENZR and 22Rv1 in ( D )] and unpaired two-tailed Student’s t -test [for LNCaP in ( D )]. In ( G , H , J , L ), P values were determined by one-way ANOVA with Tukey’s multiple comparisons test. In ( M ), P values were determined by permutation test. In ( N ), P values were determined by chi-square test. * P < 0.05, ** P < 0.01; ns, not significant. Exact P values are listed in Appendix Table . .
Techniques Used: RNA Sequencing, Knockdown, Control, Marker, Western Blot, Activity Assay, Transfection, Expressing, Two Tailed Test
Figure Legend Snippet: Reagents and tools table
Techniques Used: Recombinant, Sequencing, Control, Transfection, Membrane, Reverse Transcription, Software, Microarray, Subcloning, shRNA, Cell Viability Assay, Viability Assay, Reporter Assay, In Situ, Enzyme-linked Immunosorbent Assay, Phospho-proteomics, Extraction, Bicinchoninic Acid Protein Assay, Magnetic Beads, Gel Extraction, Purification, Ligation, Mutagenesis, Chromatin Immunoprecipitation
Related Articles
Control:Article Title: PlexinD1 is a driver and a therapeutic target in advanced prostate cancer. Article Snippet: Aggressive prostate cancer (PCa) variants associated with androgen receptor signaling inhibitor (ARSI) resistance and metastasis remain poorly understood.. Here, we identify the axon guidance semaphorin receptor PlexinD1 as a crucial driver of cancer aggressiveness in metastatic castration-resistant prostate cancer (CRPC).. High PlexinD1 expression in human PCa is correlated with adverse clinical outcomes. Article Title: PlexinD1 is a driver and a therapeutic target in advanced prostate cancer Article Snippet: Human PLXND1 siRNA pool was purchased from Horizon Discovery. .. Human SEMA3C , SEMA3E , and |